Clinical Trial Update: Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures [Phase 2]

View source ↗

Summary

Phase 2 trial of cannabidiol oral solution in pediatric participants with treatment-resistant childhood absence seizures was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Absence Epilepsy

Drugs mentioned

• Cannabidiol Oral Solution (cannabidiol)

Snippet

Sponsor: Radius Pharmaceuticals, Inc. | Conditions: Childhood Absence Epilepsy | Phase 2 | Status: TERMINATED | Results posted: 2023-07-21